Meta-Analysis on the Correlation Between APOM rs805296 Polymorphism and Risk of Coronary Artery Disease

Sun, Hongyan; Shen, Dong; Zhang, Chunhong; Huang, Dangsheng; Wang, Yumei; Zhang, Liwei

doi:10.12659/msm.894829

Cited by 4 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28,29 Apolipoprotein M has also been studied for its role in other cardiovascular diseases including coronary artery disease, where low levels of ApoM were associated with high risk of disease development. 27,33 One possible explanation for the difference between our results and other’s findings could be the difference in nature of the diseases under investigation. Now it is well established that primary and recurrent VTE are 2 different diseases and their risk markers are not similar.…”

Section: Discussioncontrasting

confidence: 93%

“…23,24 Studies have shown that genetic aberrations in ApoM that affect the expression levels are associated with higher risk of coronary artery disease and diabetes mellitus. 25 –27 Recently, genetic aberrations in ApoM have been shown to be associated with high risk of VTE recurrence in males. 28 Similarly, in a study by Memon et al, lower plasma levels of ApoM were associated with an increased risk of VTE recurrence in male patients.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Expression Level of Apolipoprotein M as a Diagnostic Marker for Primary Venous Thromboembolism

Ahmad

Sundquist

Zöller

et al. 2017

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

Recently, decreased levels of apolipoprotein M (ApoM) were shown to be associated with higher risk of recurrent venous thromboembolism (VTE) in male patients. However, the role of ApoM in primary VTE is unknown. We aimed in our study to analyze the plasma levels of ApoM in patients with VTE in order to evaluate the diagnostic importance of ApoM in primary VTE. A total of 357 patients with suspected first episode of VTE were recruited prospectively in the SCORE study. Plasma samples from 307 patients were available for quantifying the plasma levels of ApoM in patients with VTE using sandwich enzyme-linked immunosorbent assay method. Among the whole population, plasma levels (mean [standard deviation]) of ApoM were not significantly different between patients with VTE (0.72 [0.20]) and non-VTE patients (0.72 [0.16]), P = .99. Similarly, in regression analyses, no significant association of ApoM plasma levels with the risk of VTE was found on univariate (odds ratio [OR] =1.0, 95% confidence interval [CI] 0.21-4.84, P = .99) and multivariate analysis (OR = 1.25, 95% CI = 0.19-8.34, P = .819) after adjusting for age, body mass index, and smoking. Moreover, results did not differ significantly after stratification of data according to sex ( P > .05). In this study, our results do not suggest a diagnostic role for ApoM plasma levels in patients with primary VTE. Moreover, the current study suggests that role of ApoM as a risk factor may differ for primary VTE and recurrent VTE in male patients.

show abstract

Section: Discussioncontrasting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Evaluation of Expression Level of Apolipoprotein M as a Diagnostic Marker for Primary Venous Thromboembolism

Ahmad

Sundquist

Zöller

et al. 2017

Clin Appl Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…Moreover, the genotype frequency and distribution difference of rs805297 (C-1065A) and rs9404941 (T-855C) inindividuals with T2DM and healthy controls was not significant. Xu et al 11 . suggested that ApoM rs9404941 (T-855C) predicts highincidenceof CAD 8 .…”

Section: Discussionmentioning

confidence: 99%

Interaction Between Apolipoprotein M Gene Single-Nucleotide Polymorphisms and Obesity and its Effect on Type 2 Diabetes Mellitus Susceptibility

Liú

Pan

Pei

et al. 2020

Sci Rep

View full text Add to dashboard Cite

this study investigated the correlation of four single nucleotide polymorphisms (Snps) in Apolipoprotein M (ApoM) with the risk of type 2 diabetes mellitus (T2DM) and effects of the interactions of this gene and obesity. The effects of SNP and obesity interaction on T2DM was examined by generalized multifactor dimensionality reduction (GMDR) combined with the logistic regression model. T2DM patient-control haplotype was analyzed in silico using the haplotype analysis algorithm SHesis. The rs805296-C allele or 724-del allele indicted high risk of T2DM. The incidence of T2DM in individuals with rs805296-C allele polymorphism (TC + cc) was higher than those without (tt), adjusted oR (95%CI) = 1.29 (1.10-1.66) (p < 0.001). Moreover, the individuals with 724-delallele have a higher risk of T2DM compared to those with 724-ins variants, adjusted OR (95%CI) = 1.66 (1.40-2.06), p < 0.001. GMDR analysis suggested that the interaction model composed of the two factors, rs805296 and obesity, was the best model with statistical significance (P value from sign test [P sign ]=0.0107). The T2DM risk in obese individuals having TC or CC genotype was higher than non-obese individuals with tt genotype (oR = 2.38, 95% CI = 1.58-3.53). Haplotype analysis suggests that rs805297-C and rs9404941-C alleles haplotype indicate high risk of T2DM, OR (95%CI) = 1.62 (1.29-2.16), p < 0.001. Our results suggested that rs805296 and 724-del minor allele of ApoM gene, interaction of rs805296 and obesity, rs805297-C and rs9404941-C alleles haplotype were indicators of high T2DM risk. Among adults in China, the estimated overall prevalence ofdiabetes was 10.9%, and that for prediabetes was 35.7%. Thus, the prevalence of type 2 diabetes mellitus (T2DM) in China is the highest in the world 1 , and the number of patients with T2DM will be about 438 million in 2030 2,3. Unfortunately, the incidence of T2DM will continue to increase in the next decades in many countries, including China, due to longevity of human life and obesity 4. The development and progression of T2DM are believed to be closely correlated with the interaction of multiple susceptibility genes and gene interactions with the environment 5-7. Human apolipoprotein M gene is structurally conserved across species and located at the human chromosome 6p21.33 8,9. ApoM is reported to be highly expressed in liver and kidneys, but weakly expressed in other human tissues 10. Previous studies reported associations between ApoM gene variations and human diseases, including CAD and T2DM; however, these observations remain controversial 11-15. In Chinese populations, Xu et al. 11 showed the ApoM rs9404941 (T-855C) polymorphism predicts a high incidence of CAD. Furthermore, ApoM rs805296 (T-778C) polymorphism was closely related with the incidence of either type 1 or type 2 diabetes 12,13. However, the association of Apo Mgene polymorphism in rs805296 (T-778C) and the risk of T2DM was found in another independent study based on Southern Chinese population 14. Emerging evidence showed that genetic and ...

show abstract

“…In a few studies on human subjects presenting this mutation, there is an association with an increased risk of CVD. While most of these studies are underpowered, the collective conclusion in a meta-analysis of the results showed an increased risk of CVD and suggested that low levels of apoM caused by rs805296 may be a risk factor for CVD [56]. Importantly to remember, a study on the general Danish population was not able to identify any associations between plasma apoM and the risk of CVD [33].…”

Section: Apom/s1p Atherogenesis and Cvdmentioning

confidence: 99%

Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system

Mattisson

Christoffersen

2021

Atherosclerosis

View full text Add to dashboard Cite

Apolipoprotein M (apoM) is a member of the lipocalin superfamily and is predominantly associated with highdensity lipoprotein (HDL). It was found that apoM is the chaperon to the bioactive sphingolipid, sphingosine-1phosphate (S1P). Several studies have since contributed to expand the knowledge on apoM, S1P, and the apoM/ S1P-complex in cardiovascular diseases. For instance, the HDL-bound apoM/S1P complex serves as a bridge between HDL and endothelial cells, maintaining a healthy endothelial barrier. Evidence indicates, however, that the apoM/S1P complex may has both protective and harmful effects on the cardiovascular system, which suggests the need for more research to understand the interplay between these molecules. This review aims to shed light on the most recent findings on apoM/S1P-signaling and its impact on endothelial dysfunction, inflammation, and cardiovascular diseases. Finally, it will be discussed whether drugs that target apoM and/or S1Psignaling may be beneficial to patients with cardiovascular and inflammatory diseases.

show abstract

Meta-Analysis on the Correlation Between APOM rs805296 Polymorphism and Risk of Coronary Artery Disease

Cited by 4 publications

References 29 publications

Evaluation of Expression Level of Apolipoprotein M as a Diagnostic Marker for Primary Venous Thromboembolism

Evaluation of Expression Level of Apolipoprotein M as a Diagnostic Marker for Primary Venous Thromboembolism

Interaction Between Apolipoprotein M Gene Single-Nucleotide Polymorphisms and Obesity and its Effect on Type 2 Diabetes Mellitus Susceptibility

Apolipoprotein M and its impact on endothelial dysfunction and inflammation in the cardiovascular system

Contact Info

Product

Resources

About